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Abstract 
Background: Chronic hepatitis B virus infection (HBV) may reactivate during the course 
of the disease and is called spontaneous relapse. The purpose of this study was to evaluate 
the incidence of relapse of hepatitis in subjects with inactive HBV carriers. 
Methods: This follow-up study was performed on 785 patients with inactive HBV carriers 
that were followed-up at six month intervals. The presence of serum HBsAg and anti-HBe, 
without HBeAg, HBV DNA levels <2000 IU/ml with normal alanine aminotransferase 
(ALT) levels was defined as inactive carriers. Patients who developed ALT ≥80 IU/L with 
HBV DNA levels ≥2000 IU/ml were considered as spontaneous relapse. 
Results: Seven hundred- eighty five cases (441 males, 344 females) of chronic HBV 
infected individuals were followed-up. The mean age at the entrance of the study was 
30.5±11.8 years. The mean follow-up duration was 5.9±5 years. Relapse was seen in 35 
(4.5%) cases,  in 27 out of 441 (6.1%) males and in 8 out of 344 (2.3%) females and in 
4.2% subjects ≥30 years versus in 4.7% cases of under 30 years (p>0.05). The 
development of relapse in males was higher than females (hazard ratio 2.53, 95% CI 1.2-
5.6, p=0.021), but age ≥30 or <30 years did not have effect (hazard ratio1.21, 95% CI 
0.62-2.36, p=0.58). 
Conclusions: The results show that spontaneous relapse of hepatitis may develop during 
the course of chronic HBV infection. We suggest that all patients with chronic hepatitis B, 
regardless of their age, be examined for the possibility of relapse. 
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More than 2 billion people in the world were exposed to hepatitis B virus (HBV) 
infection and 340 million subjects became chronically infected with HBV (1, 2). After 
chronic HBV infection, the natural course passes into five phases including immune 
tolerant HBeAg positive phase, immune reactive HBeAg positive phase, inactive carrier 
state, HBeAg negative reactivation phase, and HBsAg negative phase (3). Among these 
five phases, patients in immune reactive HBeAg positive phase, and HBeAg negative 
reactivation phase, should be treated with appropriate anti-viral agents but other phases 
should be followed periodically for observing the behavior of the virus in these exposed 
patients.The clinical course of each phase is different from each other and should be 
followed properly. During inactive carrier state phase, serum HBV DNA levels low 
(<2000IU/ml), and ALT levels are below the ULN (3). During the course of inactive 
carrier state, some patients may serocleared of HBsAg associated with the appearance of 
anti-HBs, and some cases may develop hepatocellular carcinoma and some of them persist 
this phase indefinitely (4).  
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The most important issue during this course is finding 
spontaneous reactivation of hepatitis (3, 5). Since chronic 
hepatitis B virus infection (HBV) may reactivate during the 
course of the disease, the purpose of this study was to 
evaluate the incidence of relapse of hepatitis in subjects with 
inactive HBV carriers. 
 
 
Methods 
From April 2005 to September 2016, 785 patients with 
chronic HBV who refer to infections clinic of Ayatollah 
Rouhani Hospital were selected and followed-up at six 
months. Individuals, who had HCV ab positive or cirrhosis 
or liver cancer and did not refer for any reason or did not do 
the necessary tests, were excluded from the study. The 
presence of serum HBsAg and anti-HBe, without HBeAg, 
HBV DNA levels <2000 IU/ml with normal alanine 
aminotransferase (ALT) levels in three occasions 12 months 
apart was defined as inactive carriers (6, 7).  
These cases were followed-up at six month intervals 
regarding HBsAg, anti-HBs, ALT, α-fetoprotein and liver 
sonography. HBV DNA was assessed every two years. 
Patients who developed ALT ≥80 IU/L with HBV DNA 
levels ≥2000 IU/ml were considered as spontaneous 
reactivation of the virus. The viral markers were tested in 
enzyme-linked immunosorbent assay (ELISA) (HBsAg, 
from Bio Merieux, France; anti-HBs from Radim Italy, 
hepatitis B e antigen [HBeAg], two different kits produced 
from Dia.Pro Diagnostic BioProbes, Italy).  
In these cases, serum HBV DNA levels were measured. 
For the isolation of HBV DNA, we used the QIAamp 
DNAkit (Qiagen, Germany). All processes were performed 
according to the manufacturer’s instructions. For the 
quantification of HBV DNA, we used Rotor-Gene 3000 
(Corbett Research, Australia) using the Artus HBV RG PCR 
kit (Qiagen, Germany).  
According to the manufacturer’s instructions, the 
sensitivity of the test was 3·8 IU/ml (1 IU= 7 copies/ml). The 
study was approved by the Infectious Diseases and Tropical 
Medicine Research Center of Babol University of Medical 
Sciences and the research ethics committee approved the 
study.  
Statistical analysis: The data were collected and analyzed 
using SPSS Version 22. T-test was used to compare mean 
values. The multiple Cox proportional hazards regression 
model was used to estimate chronic HBV carrier to relapse 
with the covariates, sex, and age <30 or ≥30 years. The time 
to persistence of chronic HBV infection without 
development of relapse data was plotted using a Kaplan–
Meier graph. The log rank test was used to compare the 
persistence of HBV carriers to development of relases with 
the same covariates. Differences with a p-value of <0.05 
were considered significant. All P-values are two-tailed. 
 
 
Results 
During the study period, 785 cases (441 males, 344 
females) of chronic HBV infected individuals were selected 
and followed-up.  
The mean age of the patients at the entrance of the study 
was 30.5±11.8 years.The mean years of follow-up were 
5.9±5 years. During the follow-up period, relapse was seen 
in 35 (4.5%) cases.  
The mean age of the relapse cases was 32.3±10.7 years. 
Relapse was seen in 8 out of 344 (2.3%) females and in 27 
out of 441 (6.1%) was males. Among the 785 cases at the 
entrance of the study, 358 (45.6%) cases were over 30 years 
of age. Relapse was seen in 4.2% subjects ≥ 30 years versus 
in 4.7% cases of under 30 years (p>0.05) (table 1).  
 
Table1. Comparison of healthy carriers Anti Hbe+ by age 
and gender 
 
variable Relapse 
N (%) 
No relapse 
N (%) 
HR:95%CI, p value 
Sex  
Female 
Male  
 
8 (2.3%) 
27(6.1%) 
 
336(97.8%) 
414(93.9%) 
 
HR*: 2.53, 95%CI 
1.2-5.6, p=0.021 
Age(year)  
≥ 30 
< 30 
 
15(4.2%) 
20(4.7%) 
 
343(95.8%) 
407(95.3%) 
 
HR** 1.21, 95%CI 
0.62-2.36, p=0.58  
*Male/Female    ** age<30/≥30 The Data were Analyzed with t-test 
 
Survival analysis showed that the mean time for the lack 
of the development of relapse was 303.9 months (95% CI, 
296.8-310.9). The mean time in the males was 264.9 
(95%CI, 256-273) and for females was 313 (95% CI, 306-
321) months (p=0.019) (figure 1).  
Cox regression model showed the development of relapse 
in males was 2.53 times higher than females (HR=2.53, 
95%CI, 1.2-5.6, P=0.021), but the age ≥30 or < 30 years had 
no effect (HR=1.21, 95% CI, 0.62-2.36, P=0.58).  
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Figure 1. Estimated time of Anti HBe+ healthy carriers 
relaps by gender 
 
Discussion 
In this study, the relapse rate in anti HBe + carriers was 
4.5% which was similar to the Kumar study. Follow-up of 
asymptomatic anti-HBe positive patients to find out those 
who has relapse and anti-viral therapy is necessary. Kumar et 
al. in India followed-up 217 cases of asymptomatic anti-HBe 
positive patients for a median follow-up of 69 months and 
found that ALT flared up in 43 cases (annual rate of 4.3%). 
They showed that age >30 years at presentation, male sex, 
and presence of precore mutants were correlated with ALT 
flare-up (8). It is estimated that about 300 million individuals 
are in this phase. More recently, the term “inactive carrier 
state” has been proposed due to the possibility of reversing 
this condition. Long-term follow-up studies showed that the 
vast majority has a sustained biochemical remission and very 
low risk of progression to cirrhosis or hepatocellular 
carcinoma (HCC) (9, 10). Hardly, some patients can develop 
HCC and up to 34% of these patients may have a 
spontaneous reactivation during follow-up, with or without 
sero-reversion to HBeAg. The risk of reactivation is higher 
in the following years after HBeAg seroconversion and 
decreases with time, although it can be present after years of 
inactivity. The occurrence of multiple episodes of 
reactivation or sustained reactivation can cause progressive 
liver damage and even hepatic decompensation (11, 12). In 
Portugal, Magalhaes and Pedroto followed-up 100 cases of 
inactive carriers for 4.6 years and found reactivation in 10% 
of their cases (13). Some studies reported that HBV 
reactivation occurred in 10-34% of their patients (14, 15). De 
Franchis et al followed-up 68 cases of inactive carriers with 
a mean 10.8 years and found HBV reactivation in 4.4% of 
their cases (7).  
Villeneuve et al. followed 200 cases in the Canada and 
follwoed them up in 16 years and found HBV reactivation in 
the 0.5% of their cases (16). Manno et al. in Italy followed-
up 296 cases with a mean follow-up of 30 years and found 
2.1% HBV reactivation (17). It is believed that 
immunological control of the infection by these cases is 
associated with good long term prognosis with low risk of 
developing cirrhosis and hepatocellular carcinoma (16, 18, 
19). In our study, we have not found any case of cirrhosis or 
hepatocellular carcinoma. Other researchers also reported a 
few cases of HCC in their cases and they believed that was 
related to cofactors like alcohol drinking and metabolic 
disorders (18).  
In our study, no cases used alcohol consumption due to 
our advisement for not drinking of this food due to harmful 
for them. In conclusion, the results show that the 
spontaneous relapse of hepatitis may develop during the 
course of chronic HBV infection. Relapse in males was 
higher. Age ≥30 or <30 years had no effect for the 
development of relapse. 
Not referring the patients due to lack of knowledge of the 
dangers of the disease, the lack of access to patient’s contact 
numbers and the cost of the tests were the limitations of the 
study. Due to the financial limitations, the measurement of 
viral load was not done in some patients.  
In conclusion, although the rate of relapse in anti HBe
+
 
healthy carriers is low, however, considering the risk of 
relapse and irreparable complications, it is important to 
follow-up the healthy carriers, specially in the first years of 
the disease.  
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